Excessive daytime sleepiness: an emerging marker of cardiovascular risk
- PMID: 35102000
- PMCID: PMC9731316
- DOI: 10.1136/heartjnl-2021-319596
Excessive daytime sleepiness: an emerging marker of cardiovascular risk
Abstract
Excessive daytime sleepiness (EDS) is classically viewed as a consequence of insufficient sleep or a symptom of sleep disorders. Epidemiological and clinical evidence have shown that patients reporting EDS in tandem with sleep disorders (e.g., obstructive sleep apnoea) are at greater cardiovascular risk than non-sleepy patients. While this may simply be attributable to EDS being present in patients with a more severe condition, treatment of sleep disorders does not consistently alleviate EDS, indicating potential aetiological differences. Moreover, not all patients with sleep disorders report EDS, and daytime sleepiness may be present even in the absence of any identifiable sleep disorder; thus, EDS could represent an independent pathophysiology. The purpose of this review is twofold: first, to highlight evidence that EDS increases cardiovascular risk in the presence of sleep disorders such as obstructive sleep apnoea, narcolepsy and idiopathic hypersomnia and second, to propose the notion that EDS may also increase cardiovascular risk in the absence of known sleep disorders, as supported by some epidemiological and observational data. We further highlight preliminary evidence suggesting systemic inflammation, which could be attributable to dysfunction of the gut microbiome and adipose tissue, as well as deleterious epigenetic changes, may promote EDS while also increasing cardiovascular risk; however, these pathways may be reciprocal and/or circumstantial. Additionally, gaps within the literature are noted followed by directions for future research.
Keywords: hypertension; inflammation; obesity.
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: VS has consulted for Baker Tilly, Respicardia, Bayer and Jazz Pharmaceuticals, and is on the Scientific Advisory Board for Sleep Number Corporation.
Figures


References
-
- Wheeler EO, White PD. Insomnia due to left ventricular heart failure unrecognized as such and inadequately treated. J Am Med Assoc. 1945;129:1158. - PubMed
-
- Jennum PJ, Plazzi G, Silvani A, Surkin LA, Dauvilliers Y. Cardiovascular disorders in narcolepsy: Review of associations and determinants. Sleep Med Rev. 2021;58:101440. - PubMed
-
- Black J, Reaven NL, Funk SE, McGaughey K, Ohayon MM, Guilleminault C, Ruoff C. Medical comorbidity in narcolepsy: Findings from the burden of narcolepsy disease (bond) study. Sleep Med. 2017;33:13–18 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical